C.R. Bard, Inc. (NYSE:BCR) Stake Raised by Paloma Partners Management Co

Paloma Partners Management Co increased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 506.8% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 12,513 shares of the medical instruments supplier’s stock after buying an additional 10,451 shares during the period. Paloma Partners Management Co’s holdings in C.R. Bard were worth $3,111,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. SRS Capital Advisors Inc. increased its stake in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares during the period. Burns J W & Co. Inc. NY increased its stake in shares of C.R. Bard by 1.3% in the first quarter. Burns J W & Co. Inc. NY now owns 1,581 shares of the medical instruments supplier’s stock worth $393,000 after buying an additional 21 shares during the period. Creative Planning increased its stake in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares during the period. Blair William & Co. IL increased its stake in shares of C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock worth $865,000 after buying an additional 30 shares during the period. Finally, Pennsylvania Trust Co increased its stake in shares of C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock worth $308,000 after buying an additional 35 shares during the period. Hedge funds and other institutional investors own 87.50% of the company’s stock.

C.R. Bard, Inc. (NYSE BCR) traded down 0.32% on Friday, hitting $320.38. 1,296,670 shares of the stock were exchanged. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27. The company has a market cap of $23.20 billion, a P/E ratio of 42.06 and a beta of 0.59. The company’s 50 day moving average price is $317.56 and its 200-day moving average price is $277.60.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the consensus estimate of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a return on equity of 49.89% and a net margin of 14.99%. C.R. Bard’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business earned $2.54 earnings per share. Equities research analysts predict that C.R. Bard, Inc. will post $11.78 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 4th. Stockholders of record on Monday, July 24th will be paid a $0.26 dividend. The ex-dividend date is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.32%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.

COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (NYSE:BCR) Stake Raised by Paloma Partners Management Co” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/07/30/paloma-partners-management-co-increases-position-in-c-r-bard-inc-nysebcr-updated-updated-updated.html.

A number of brokerages have recently commented on BCR. BidaskClub downgraded shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Monday, July 17th. BMO Capital Markets restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. Finally, Raymond James Financial, Inc. downgraded shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a report on Wednesday, April 26th. Eight investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $284.89.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply